LifeSci Capital initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $87 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX:
- Tectonic Therapeutic Reports Q1 2025 Financial Results
- Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45
- Tectonic Therapeutic Announces Phase 1b Trial Results
- Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic
- Tectonic Therapeutic price target raised to $85 from $51 at Mizuho